KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.5 billion.

  • Vertex Pharmaceuticals' Goodwill & Intangibles fell 2093.14% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 2093.14%. This contributed to the annual value of $1.9 billion for FY2024, which is 134.03% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $1.5 billion for Q3 2025, which was down 2093.14% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Goodwill & Intangibles registered a high of $1.9 billion during Q4 2023, and its lowest value of $1.4 billion during Q2 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' median Goodwill & Intangibles value was $1.7 billion (recorded in 2022), while the average stood at $1.6 billion.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first surged by 2176.79% in 2023, then crashed by 2093.14% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $1.4 billion in 2021, then rose by 21.49% to $1.7 billion in 2022, then rose by 13.87% to $1.9 billion in 2023, then decreased by 1.34% to $1.9 billion in 2024, then decreased by 20.7% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.5 billion during Q1 2025.